1. Home
  2. |Insights
  3. |Draft Investment Accounts Instructions Issued by Saudi Arabian Capital Market Authority for Public Consultation

Draft Investment Accounts Instructions Issued by Saudi Arabian Capital Market Authority for Public Consultation

Client Alert | 1 min read | 01.15.16

As part of the efforts of the Saudi Arabian Capital Market Authority (the CMA) to develop the Saudi Arabian capital market and protect investors, and pursuant to the Capital Market Regulations as enacted by Royal Decree Number M/30 dated 2/6/1424 H / 1 August 2003, the Board of the CMA has published draft Investment Accounts Instructions (the Draft Instructions) on the CMA's website to allow concerned and interested parties to provide their comments and observations.

The Draft Instructions aim to regulate the opening and operation of investment accounts held by authorized persons licensed to undertake dealing, managing, or custody activities and to define the related investment account controls and supervisory rules.

The CMA will accept comments and observations on the Draft Instructions via email to Rules.Regulations@cma.org.sa no later than Monday 29/4/1437 H / 8 February 2016. The CMA notes that it will study and consider all comments and observations prior to issuing final Instructions.

Insights

Client Alert | 5 min read | 01.27.25

After Trump Executive Orders, FDA Removes Diversity Guidance From Website

Days after President Trump issued an executive order (EO) taking aim at diversity, equity, and inclusion (DEI) programs and prohibiting federal recognition of gender identity apart from biological sex, previously issued draft guidance on diversity in clinical trials was removed from the website of the U.S. Food and Drug Administration (FDA). While the removed guidance was in draft form, it is highly unusual for FDA to revoke or alter draft guidance without issuing a statement or further guidance. This move raises questions about the applicability of statutory obligations to submit clinical trial Diversity Action Plans and the agency’s current thinking on best practices for clinical development....